News | October 18, 2019
Positive data for VP-102 (cantharidin 0.7% Topical Solution) from Verrica Pharmaceuticals, Inc. are being presented in poster form at the Annual Fall Clinical Dermatology Conference in Las Vegas. Company’s lead product...
With a surge in new research over the last decade, dermatologists are learning more about Hidradenitis Suppurativa, comorbidities, and quality of life impact. In the first of a series, Steven Cohen, MD discusses HS with host Adam Friedman, MD.
News | August 16, 2019
Fungal diagnostic preparations can assist the accurate diagnosis of cutaneous fungal infections. A survey from a team at the George Washington University (GW) identifies barriers that prevent their consistent use. The study is...
Verrica Pharmaceuticals: Positive Data for VP-102 for Molluscum Contagiosum, Warts
Positive Top-line Results Seen in Pivotal Phase 3 Clinical Trial of StrataGraft Regenerative Tissue Deep Partial-thickness Thermal Burns
Ask an Expert
With a surge in new research over the last decade, dermatologists are learning more about Hidradenitis Suppurativa, comorbidities, and quality...
Adam Friedman, MD, FAAD; and Steven Cohen, MD
Positive Results for Aclaris Therapeutics’ A-101 45% Topical Solution in Pivotal Phase 3 Trial for the Treatment of Warts
Summer AAD News: Understanding the Dermatologist’s Role in Reducing Skin-related Side Effects from New Cancer Drugs
Highlights from Day 3 at DERM2019: Hyperhidrosis, Bug Bites, Sunscreen, and More